This article is for informational purposes only and does not provide medical advice, diagnosis, or treatment. Consult a qualified healthcare professional about your health or before changing treatment. Do not delay medical care because of something you read here.
Update, October 2026: BPC-157 and TB-500 are now available. Log in to your Rebody account to speak with a clinician and get started. Some information below may be out of date.
Key Takeaways
- BPC-157 is a fifteen-amino-acid peptide with direct rat tendon and ligament studies. It has no controlled human trial for injury recovery.
- TB-500 is a synthetic seven-amino-acid fragment of thymosin beta-4. FDA's 2026 review identified no human studies and no in-vivo wound studies of TB-500 itself.
- No controlled study has tested the two together. The combination's advantage is one-vial handling, not a higher evidence tier.
- Neither peptide is FDA-approved. Both left the FDA's Category 2 list in April 2026, and a July 2026 advisory vote on the 503A bulk list is not final.
- Both appear on the World Anti-Doping Agency Prohibited List.
- Amount, route, and schedule are a clinician's decision after evaluation.
The difference between TB-500 and BPC-157 comes down to evidence. BPC-157 has rat tendon and ligament data. TB-500, a thymosin beta-4 fragment, has almost no direct research of its own.
Neither peptide has a controlled human trial for injury recovery, and no study has tested them together. Before comparing prescription BPC-157 with a BPC-157 and TB-500 combination, start with the tissue question, then the evidence behind each molecule.
What is the difference between TB-500 and BPC-157?
BPC-157 is the first comparison for tendon and ligament research, TB-500 owns the actin-fragment lane, and the blend wins only on convenience.
Comparing the two peptides
| Peptide | Mechanism | Evidence base | Monitoring | Regulatory status |
|---|---|---|---|---|
| BPC-157 | Proposed local repair signaling (growth factor receptors, new blood vessels, nitric oxide). Molecular target not identified. | Rat tendon, ligament, and muscle injury models. A few small, uncontrolled human pilot studies. | Set by the clinician. No validated marker of response. | Not FDA-approved. Off Category 2 since April 2026. WADA-prohibited. |
| TB-500 | Actin-binding fragment of thymosin beta-4. Activity may depend on the smaller fragments it breaks into. | No human studies. No in-vivo wound studies of TB-500 itself. One cell study showed no wound-closure difference. | Set by the clinician, without human safety data to anchor it. | Same status as BPC-157. WADA-prohibited. |
| Combination vial | Both mechanisms in one fixed ratio. | Never tested as a combination in a controlled study. | Harder, because a reaction cannot be traced to one active. | Same status as each component. |
How BPC-157 works
BPC-157 is a fifteen-amino-acid peptide. It is a partial sequence of a larger body protection compound found in gastric juice, which explains the early focus on the gut.
For tendon and ligament questions, the relevant work is local and cellular. BPC-157 appears to act on the cells that rebuild connective tissue after injury:
- In tendon explant cultures, it increased fibroblast outgrowth, survival under stress, and migration.
- In rat tendon fibroblasts, it raised growth hormone receptor expression, which may increase those cells' response to existing growth signals.
- Researchers have also proposed roles in new blood vessel formation and nitric oxide signaling around injured tissue.
FDA's 2026 BPC-157 review states the limits plainly: the molecular target is unidentified, dose-response relationships are not established, and the mechanisms remain poorly understood.
How TB-500 works
TB-500 commonly refers to an acetylated seven-amino-acid fragment related to thymosin beta-4 (LKKTETQ).
Thymosin beta-4 regulates actin, the protein cells use to change shape and move. It holds single actin units in reserve so cells can build filaments when they migrate, including toward a wound. The LKKTET segment inside TB-500 is the parent protein's actin-binding region.
The premise is that this fragment carries some of the parent protein's repair activity. The direct evidence is limited:
- A 2003 study applied a non-acetylated version of the fragment to skin wounds in aged mice and measured greater wound closure and collagen at day 7. That molecule was not TB-500, and the FDA noted that acetylation changes a peptide's properties enough to prevent direct extrapolation.
- In a 2024 cell study, TB-500 did not change scratch-wound closure in fibroblast cultures over 8 hours. One of its breakdown fragments produced a small effect.
- In horses and rats, injected TB-500 reached the bloodstream and was broken into shorter peptides within hours.
FDA identified no in-vivo wound studies and no toxicity studies of TB-500. Full thymosin beta-4 evidence does not transfer to the fragment.
Can TB-500 and BPC-157 be stacked together, and what does the safety data show?
TB-500 and BPC-157 are stacked because their proposed mechanisms look complementary: local tissue signaling on one side, actin and cell movement on the other. The data do not yet support that logic.
No controlled trial has tested the combination in people or animals. The nearest example is a 2021 knee pain report in which some patients received compounded thymosin beta-4 with BPC-157. That report was uncontrolled, and thymosin beta-4 is not TB-500.
Each active on its own:
- BPC-157: Small human pilot studies reported no serious adverse events, though none was designed to establish safety.
- TB-500: FDA identified no human exposure data and no acute, repeat-dose, genetic, reproductive, or carcinogenicity studies. Human safety is unknown.
One FDA adverse event report describes a woman using an injectable BPC-157 and TB-500 product not intended for human use. She developed skin and gum darkening, and the reaction returned on rechallenge. FDA could not attribute it to either peptide. That is the attribution problem every blend carries.
Combination use is a clinical judgment rather than a default. A clinician weighs whether both rationales apply, what each active adds, and how a reaction would be traced and managed.
Comparing the route: local vs systemic administration
Route determines where a peptide goes. Local administration places it near the target tissue. Systemic administration sends it into circulation.
Route also changes risk. FDA noted greater immunogenicity concern for peptides given by injection or nasal spray than by oral or rectal routes, particularly when impurities and aggregates are not controlled. Whether any route fits is a clinician's decision.
Format is part of Rebody's approach. Beyond injectables, its clinicians prescribe other peptides as prescription peptide nasal sprays, oral troches, dissolvable strips, and gummies. BPC-157 and TB-500 are available through Rebody Health too. Start an online visit for BPC-157 or TB-500, and a licensed clinician decides whether either fits you.
What the research on BPC-157 and TB-500 has actually measured
Read the research by its endpoints. These are measurements in animals and cells, not human outcomes:
- Rat Achilles tendon, BPC-157: Transected tendons were assessed for function, load to failure, elasticity, microscopic structure, and collagen.
- Rat knee ligament, BPC-157: Transected medial collateral ligaments were assessed for function, biomechanics, microscopy, and visible repair.
- Aged mouse skin wounds, thymosin beta-4 fragment: A topical non-acetylated fragment was assessed for wound closure and collagen.
- Fibroblast scratch assay, TB-500: Wound closure did not differ from control.
- Human IV safety pilot, BPC-157: Two healthy adults received IV infusions. The study tracked safety measures, not recovery.
FDA's BPC-157 briefing identified five small clinical studies of BPC-157, all short, with limited safety reporting. For TB-500, it identified none.
The strongest studies measured tissue mechanics and structure in injured rats. They describe biology in animals and stop short of establishing recovery in people.
Which one fits which situation?
Start with BPC-157 when the question is tendon or ligament research. Start with TB-500 only when the question is the exact seven-amino-acid actin fragment. Choose the combination when both rationales are intentional and reducing injection or vial handling is worth the added attribution problem.
This is not a tie. BPC-157 wins the tendon-and-ligament research question, TB-500 owns the exact fragment question, and the blend wins the handling question.
How long do TB-500 and BPC-157 take to work, and what does a course look like?
No human study has measured onset for either peptide. The research can show how long published studies ran and what they tracked.
| Study | Peptide | Duration |
|---|---|---|
| Rat Achilles tendon (2003) | BPC-157 | 14 days |
| Rat knee ligament (2010) | BPC-157 | Up to 90 days |
| Aged mouse skin wounds (2003) | Non-acetylated fragment | 7 days |
| Fibroblast scratch assay (2024) | TB-500 | 8 hours |
| Human pilot studies (2002 to 2025) | BPC-157 | 1 day to 2 weeks |
| Human studies | TB-500 | None published |
Animal timelines do not translate to people. The studies used controlled surgical injuries in rodents, not the chronic neck, back, or tendon complaints most adults bring to a clinician.
When a clinician considers a peptide, the course is defined by a plan rather than a calendar:
- An evaluation of the injury, history, medications, and contraindications.
- One tissue-specific outcome to track, such as load tolerance, range of motion, strength, or a clinician-set milestone. A broad "recovery" score cannot show which active did anything.
- Scheduled check-ins to review that outcome and any side effects.
- Stop criteria agreed on before starting.
Vial strength, concentration, and dosage for BPC 157 and TB 500
Strength, concentration, and dose are different facts:
- Strength is the total peptide in the vial, such as 5 mg or 10 mg. It is not the amount used at one time.
- Concentration is the amount per milliliter once the vial is prepared.
- Dose is the amount prescribed per use, set by the clinician and delivered by volume at that concentration.
A combination label needs concentration and prescribed amount for each active. “10 mg blend” is ambiguous unless the label states whether that means 5 mg plus 5 mg, 10 mg of each, or another ratio.
Use the combination vial's own label. It does not automatically inherit the storage rule of either solo ingredient, and separate vials may have different beyond-use dates.
Keep the original container, lot, and label together. Hold any product exposed to freezing, excess heat, a broken seal, crack, leak, cloudiness, particles, or color change until the dispensing pharmacy advises on that formula.
Side effects and urgent symptoms
A blend retains injection-site risks and adds uncertainty about which active caused a reaction. Watch for pain, bruising, bleeding, irritation, spreading warmth or redness, drainage, red streaking, fever, facial swelling, breathing trouble, or fainting.
Human systemic safety evidence is limited for both actives, and combination safety is not established. Pregnancy, cancer or immune treatment, clotting concerns, medication interactions, and tested-athlete status require direct review.
How TB-500 and BPC-157 are legally accessed in the US
No FDA-approved drug product contains either peptide, and compounded preparations are not FDA-approved. Regulatory status has shifted during 2026:
- 2023: FDA placed both peptides in Category 2, its list of bulk substances raising significant safety concerns for compounding.
- April 2026: Both were removed from Category 2 after their nominations were withdrawn. Removal was not approval.
- July 23, 2026: At FDA's Pharmacy Compounding Advisory Committee meeting, the panel voted to recommend both for the 503A bulks list, against the recommendation of FDA's own reviewers.
Legitimate access runs through a licensed clinician who evaluates whether either peptide is appropriate, considers alternatives with stronger evidence, and prescribes only what a licensed pharmacy can lawfully dispense. For more detail, see where BPC-157's legal status stands.
Material sold online as "research use only" is not intended for human use. FDA reviews noted that typical certificates of analysis for these peptides omit testing for impurities, bacterial endotoxins, and aggregates.
Rebody is built on clinician-led care. A licensed clinician reviews goals and history and gives a direct answer on whether a peptide belongs in the plan. For either peptide, start with a consult.
Compounded medications require clinician review and, when clinically appropriate, a prescription. Compounded medications are not FDA-approved. Outcomes vary.
Frequently asked questions about TB-500 and BPC-157
Can I take BPC-157 and TB-500 every day?
Use the exact schedule printed on the prescription label. BPC-157 and TB-500 have different identities and historical schedules, so a combination label must state the amount and cadence of each active rather than borrowing a daily stack online.
What are the risks of taking TB-500?
FDA's review identified no human TB-500 exposure, pharmacokinetic, safety, or efficacy study. Injection risks include pain, bruising, contamination, and infection; a blend also makes it harder to identify which active caused a reaction. TB-500 is prohibited for tested athletes.
Is TB-500 the same as thymosin beta-4?
No. TB-500 commonly refers to a seven-amino-acid fragment related to residues 17–23 of thymosin beta-4. Thymosin beta-4 is a 43-amino-acid protein, so its human wound studies cannot be presented as TB-500 trials. The distinction matters because a BPC-157/TB-500 vial contains a fragment, not the 43-amino-acid parent protein.
What changes between 5 mg and 10 mg vials?
Five and ten milligrams usually describe total active in the vial, not the amount used at one time. Concentration, prescribed dose, frequency, days of supply, price per day, and refill timing decide which package is more practical. For a blend, the label must show whether the headline milligrams are per active or combined total.
How quickly do TB-500 and BPC-157 start working?
No human study has measured onset for either peptide. Animal studies tracked tissue changes over periods ranging from 7 days in mouse skin wounds to 90 days in rat ligaments, which is not a human timeline. A clinician sets check-in points based on the individual case.
How do you get TB-500 and BPC-157 legally in the US?
Neither peptide is an FDA-approved drug, and compounded preparations are not FDA-approved. Compounding status remains unsettled after a July 2026 advisory vote, so legitimate access runs through a licensed clinician who evaluates whether either peptide is appropriate. Products sold online as research chemicals are not intended for human use.
What is the TB-500 and BPC-157 dosage?
No human dose has been established for either peptide. Rat studies of BPC-157 used microgram or nanogram amounts per kilogram of body weight, small human pilot studies used milligram amounts by injection or infusion, and TB-500 has not been dosed in a published human study. An individual amount, if any, is set by a clinician after evaluation.
Is the BPC-157 and TB-500 combination proven to work better?
BPC-157 has closer animal tendon and ligament evidence; TB-500 has a separate actin-fragment lane. The cited literature does not compare their finished combination against either solo ingredient, so the blend's present advantage is convenience rather than a higher evidence tier.
How should milligrams be listed in a combination vial?
The label should state the quantity or concentration of each active, not only a combined headline. “10 mg blend” could describe several ratios. The prescription also needs injection volume, amount of each active delivered per use, frequency, total supply, storage, and beyond-use date. If the ratio cannot be reconstructed from the label, the package is not ready for comparison.
When is one-vial convenience worth paying for?
It matters when both ingredients have a deliberate role, and one finished vial removes a second preparation, injection, storage plan, shipment, or refill. It matters less when the prescribed frequency is unchanged or only one active answers the tissue question. Put the saved handling events beside the price premium rather than assuming a blend is automatically easier.
Bottom line
BPC-157 is the first comparison for tendon and ligament research, TB-500 owns the actin-fragment lane, and the blend wins only on convenience.
Keep reading
- BPC-157 + TB-500 Combination Injections
- BPC-157 and TB-500 Recovery Peptides
- Multi-Peptide Formulas for Soft-Tissue Recovery
Primary sources
- https://pubmed.ncbi.nlm.nih.gov/14554208/
- https://pubmed.ncbi.nlm.nih.gov/18594781/
- https://pubmed.ncbi.nlm.nih.gov/20225319/
- https://pubmed.ncbi.nlm.nih.gov/40131143/
- https://www.fda.gov/media/193343/download
- https://pubmed.ncbi.nlm.nih.gov/12581423/
- https://pubmed.ncbi.nlm.nih.gov/14500546/
- https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026
- https://www.wada-ama.org/en/resources/world-anti-doping-program/prohibited-list

